c-Myc Antibody | Affinity Biosciences

IF/ICC
Cites

1/11

c-Myc Antibody - AF6054 staining Hela cells by ICC/IF.

c-Myc Antibody - AF6054 staining A549 cells by IF/ICC.

c-Myc Antibody - Figure 3.

c-Myc Antibody - Figure 2.

c-Myc Antibody - Figure 4 |The loss of RECQL4 induces cell cycle arrest and cellular senescence.

c-Myc Antibody - Figure 1 Construction of the cell lines with different c-Myc expression.

c-Myc Antibody - FIG.

c-Myc Antibody - Figure 7 PIGU knockdown suppresses tumorigenesis of HCC cells in vivo.

c-Myc Antibody - Fig.

c-Myc Antibody - Figure 5.

c-Myc Antibody - Fig.

Product:	c-Myc Antibody
Catalog:	AF6054
Description:	Rabbit polyclonal antibody to c-Myc
Application:	WB IHC IF/ICC
Reactivity:	Human, Mouse, Rat
Prediction:	Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.:	50kDa; 49kD(Calculated).
Uniprot:	P01106
RRID:	AB_2834973

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)

Clonality:

Polyclonal

Specificity:

c-Myc Antibody detects endogenous levels of total c-Myc.

RRID:

AB_2834973
Cite Format: Affinity Biosciences Cat# AF6054, RRID:AB_2834973.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

AU016757; Avian myelocytomatosis viral oncogene homolog; bHLHe39; c Myc; Class E basic helix-loop-helix protein 39; MRTL; Myc; Myc protein; Myc proto oncogene protein; Myc proto-oncogene protein; myc-related translation/localization regulatory factor; MYC_HUMAN; Myc2; MYCC; Myelocytomatosis oncogene; Niard; Nird; Oncogene Myc; OTTHUMP00000158589; Proto-oncogene c-Myc; Protooncogene homologous to myelocytomatosis virus; RNCMYC; Transcription factor p64; Transcriptional regulator Myc-A; V-Myc avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog (avian);

Immunogens

Immunogen:

Uniprot:

P01106(MYC_HUMAN) >>Visit HPA database.

Gene(ID):

MYC(4609)

Description:

Myc a proto-oncogenic transcription factor that plays a role in cell proliferation, apoptosis and in the development of human tumors.. Seems to activate the transcription of growth-related genes.

Sequence:

P01106 MYC_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

100

Horse

100

Bovine

100

Sheep

100

Dog

100

Xenopus

100

Chicken

100

Rabbit

100

Zebrafish

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P01106 As Substrate

P01106

Site	PTM Type	Enzyme	Source
	Ubiquitination		Uniprot
S6	Phosphorylation		Uniprot
T8	Phosphorylation	P04049 (RAF1)	Uniprot
Y12	Phosphorylation		Uniprot
Y16	Phosphorylation		Uniprot
Y22	Phosphorylation		Uniprot
Y32	Phosphorylation	P00519 (ABL1)	Uniprot
K51	Sumoylation		Uniprot
K51	Ubiquitination		Uniprot
K52	Sumoylation		Uniprot
K52	Ubiquitination		Uniprot
T58	O-Glycosylation		Uniprot
T58	Phosphorylation	P49841 (GSK3B) , P28482 (MAPK1) , P49840 (GSK3A) , P53779 (MAPK10) , P45983 (MAPK8)	Uniprot
S62	Phosphorylation	Q13627 (DYRK1A) , P45984 (MAPK9) , Q00535 (CDK5) , P28482 (MAPK1) , P45983 (MAPK8) , Q92630 (DYRK2) , P53779 (MAPK10) , P42345 (MTOR)	Uniprot
S64	Phosphorylation		Uniprot
S67	Phosphorylation		Uniprot
S71	Phosphorylation	P28482 (MAPK1) , P45984 (MAPK9) , P53779 (MAPK10) , P45983 (MAPK8)	Uniprot
Y74	Phosphorylation	P00519 (ABL1)	Uniprot
T78	Phosphorylation		Uniprot
S81	Phosphorylation		Uniprot
K143	Acetylation		Uniprot
K148	Acetylation		Uniprot
K148	Sumoylation		Uniprot
K148	Ubiquitination		Uniprot
S151	Phosphorylation		Uniprot
K157	Acetylation		Uniprot
K157	Sumoylation		Uniprot
K157	Ubiquitination		Uniprot
S161	Phosphorylation		Uniprot
T244	Phosphorylation		Uniprot
S249	Phosphorylation	P68400 (CSNK2A1)	Uniprot
S250	Phosphorylation	P68400 (CSNK2A1)	Uniprot
S252	Phosphorylation	P68400 (CSNK2A1) , P48729 (CSNK1A1)	Uniprot
K275	Acetylation		Uniprot
S277	Phosphorylation		Uniprot
S279	Phosphorylation		Uniprot
S281	Phosphorylation		Uniprot
S288	Phosphorylation		Uniprot
K289	Ubiquitination		Uniprot
S293	Phosphorylation		Uniprot
K298	Ubiquitination		Uniprot
K317	Acetylation		Uniprot
K317	Sumoylation		Uniprot
K323	Acetylation		Uniprot
K323	Sumoylation		Uniprot
K323	Ubiquitination		Uniprot
K326	Sumoylation		Uniprot
K326	Ubiquitination		Uniprot
S329	Phosphorylation	P11309 (PIM1) , Q9P1W9 (PIM2)	Uniprot
S337	Phosphorylation		Uniprot
T343	Phosphorylation		Uniprot
S344	Phosphorylation		Uniprot
S347	Phosphorylation	P68400 (CSNK2A1)	Uniprot
S348	Phosphorylation	P68400 (CSNK2A1)	Uniprot
T350	Phosphorylation		Uniprot
K355	Sumoylation		Uniprot
K355	Ubiquitination		Uniprot
T358	Phosphorylation	Q13177 (PAK2)	Uniprot
K371	Acetylation		Uniprot
S373	Phosphorylation	Q13177 (PAK2)	Uniprot
K389	Sumoylation		Uniprot
K389	Ubiquitination		Uniprot
K392	Sumoylation		Uniprot
K392	Ubiquitination		Uniprot
K398	Sumoylation		Uniprot
K398	Ubiquitination		Uniprot
T400	Phosphorylation	Q13177 (PAK2)	Uniprot
S405	Phosphorylation		Uniprot
K412	Sumoylation		Uniprot
K412	Ubiquitination		Uniprot
K422	Ubiquitination		Uniprot
K430	Sumoylation		Uniprot
K430	Ubiquitination		Uniprot

Research Backgrounds

P01106_MYC_HUMAN

Function:

Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells. Functions with TAF6L to activate target gene expression through RNA polymerase II pause release (By similarity).

PTMs:

Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2 leads to the stabilization of MYC (By similarity). Phosphorylation at Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylated at Ser-62 by DYRK2; this primes the protein for subsequent phosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome.

Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28 but by USP36, due to the lack of interaction between isoform 3 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex. Ubiquitinated by TRIM6 in a phosphorylation-independent manner (By similarity).

Subcellular Location:

Nucleus>Nucleoplasm. Nucleus>Nucleolus.

Subunit Structure:

Efficient DNA binding requires dimerization with another bHLH protein. Binds DNA as a heterodimer with MAX. Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A and KDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) with FBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimer MYC:MAX interacts with ABI1; the interaction may enhance MYC:MAX transcriptional activity. Interacts with TRIM6 (By similarity). Interacts with NPM1; the binary complex is recruited to the promoter of MYC target genes and enhances their transcription. Interacts with CIP2A; leading to the stabilization of MYC.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle. (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)

References

1). Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. NUCLEIC ACIDS RESEARCH, 2020 (PubMed: 32710621) [IF=16.6]

Application: WB Species: human Sample: HepG2

Figure 3. Effect of A22 on gene transcription and translation in HepG2 cells. The mRNA levels of BCL-2 and BAX (A), as well as C-KIT, KRAS, C-MYC and VEGF (B) in HepG2 cells were analyzed by using qRT-PCR after incubation with increasing concentration of A22 for 12 h. (C) Effects of A22 on protein expressions of C-MYC, VEGF, C-KIT and BCL-2 in the presence or absence of increasing concentration of A22 for 24 h, which were quantitatively analyzed (D).

2). RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer. Cancer Biology & Medicine, 2021 (PubMed: 33628589) [IF=5.6]

Application: WB Species: human Sample: ESCC cells

Figure 4 |The loss of RECQL4 induces cell cycle arrest and cellular senescence. . (D) The protein levels of c-myc, p21, cyclin D, CDK6, cyclin E, Bax, and Bcl-2 were determined by Western blot in stable Tet-on inducible RECQL4 knockdown cell lines (KYSE30 and TE-1 cells) (+Dox) and controls (–Dox). Experiments were independently repeated 3 times. All data indicate the mean ±SD. *P < 0.05; **P < 0.01; ***P < 0.001.

3). Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells. Frontiers in Pharmacology, 2020 (PubMed: 32362830) [IF=5.6]

Application: WB Species: Human Sample: pancreatic cancer cells

Figure 1 Construction of the cell lines with different c-Myc expression. The expression of c-Myc in human pancreatic cancer cells (Colo357, HS766T, PANC-1, BxPC3, SW1990, PIC-35) was detected via (A) Quantitative real-time polymerase chain reaction (qRT-PCR) and (B) western blot (n = 3). The expression of c-Myc in PANC-1 cells transfected with si-c-Myc or siRNA negative control was detected via (C) qRT-PCR and (D) western blot (** p < 0.01 vs control, n = 3). The expression of c-Myc in SW1990 cells transfected with pcDNA-c-Myc or empty vector pcDNA was detected via (E) qRT-PCR and (F) western blot (** p < 0.01 vs control, n = 3).

4). Fractalkine Aggravates LPS-induced Macrophage Activation and Acute Kidney Injury via Wnt/β-catenin Signaling Pathway. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021 (PubMed: 34101346) [IF=5.3]

5). PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape. LIFE SCIENCES, 2020 (PubMed: 32971102) [IF=5.2]

Application: IHC Species: Human Sample: HCC cells

Figure 7 PIGU knockdown suppresses tumorigenesis of HCC cells in vivo. (A) Relative protein expression levels of PIGU, c-Myc, MMP2, and cleaved-caspase 3 in tumor tissues measured by Western blotting. The densitometry of each band was normalized with that of respective β-actin. (B) The expression of PIGU, c-Myc, MMP2, and cleaved-caspase 3 in tumor tissues detected by immunohistochemistry staining. Scale bar = 50 μm. Data are means ± SD, n = 6. *P < 0.05 compared with shRNA-NC group. PIGU, phosphodylinositol glycan anchor biosynthesis class U; MMP2, matrix metalloproteinase 2; SD, standard deviation; NC, negative control.

6). Phillygenin Inhibits TGF-β1-induced Hepatic Stellate Cell Activation and Inflammation: Regulation of the Bax/Bcl-2 and Wnt/β-catenin Pathways. Inflammation, 2024 (PubMed: 38393550) [IF=4.5]

Application: WB Species: Mouse Sample: mHSC

Fig. 10 Efects of PHI on Wnt/β-catenin signaling pathway-related proteins. a Western blotting analyses of Wnt1, β-catenin, GSK-3β, p-GSK-3β, c-Myc, and Cyclin D1 in mHSCs.

7). Neuron Specific Enolase Promotes Metastasis by Activating the Wnt/β-catenin Pathway in Small Cell Lung Cancer. Translational Oncology, 2020 (PubMed: 33618068) [IF=4.5]

Application: WB Species: Human Sample: SCLC cells

Fig. 4 Wnt/β-catenin signaling pathway was activated in NSE-overexpressing SCLC cells. (A) Signal pathway enrichment investigation between high NSE expression group and low NSE expression group was enriched by GSEA. (B, C) NSE overexpression activated Wnt/β-catenin pathway and upregulated the expression of downstream target genes (c-Myc and Slug). The protein (B) and mRNA (C) expression of β-catenin, c-Myc and Slug in NSE-overexpressing H446 cells were tested by western blotting and qRT-PCR, respectively. (D, E) Silencing NSE repressed Wnt/β-catenin signaling pathway. The protein (D) and mRNA (E) expression of β-catenin, c-Myc and Slug in NSE-silencing H69 cells. Results was representative of three independent experiments. Data are presented as mean values ± SD. *p < 0.05 using the two-sided Student's t-test. ns: no significance.

8). Upregulation of E‑cadherin expression mediated by a novel dsRNA suppresses the growth and metastasis of bladder cancer cells by inhibiting β-catenin/TCF target genes. INTERNATIONAL JOURNAL OF ONCOLOGY, 2018 (PubMed: 29620261) [IF=4.5]

9). Therapeutic inhibition of PHF21B attenuates pathological cardiac hypertrophy by inhibiting the BMP4/GSK3β/β-catenin axis. European journal of pharmacology, 2025 (PubMed: 39900327) [IF=4.2]

10). Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells. Bioengineered, 2021 (PubMed: 34823423) [IF=4.2]

Application: WB Species: Human Sample: MKN-45 and Hs746T cells

Figure 5. UBAP2L functions by regulating Wnt/β-catenin signaling a. The levels of β-catenin in cytoplasm and nuclei were analyzed by western blot after knockdown of UBAP2L. b and c. The intracellular distribution of β-catenin was observed through immunofluorescence staining. (the scale bar represented 50 μm, arrows indicated nuclear location of β-catenin) d. The expression levels of several Wnt/β-catenin targets, including cyclin D1, AXIN-2, and c-MYC, were examined by western blot. e. The cellular level of β-catenin was detected after overexpression of β-catenin. f. The levels of nuclear β-catenin and cellular cyclin D1 were detected in AGS cells after knockdown of UBAP2L and/or overexpression of β-catenin. g. Cell viability was measured by CCK-8 assay. h-k. Cell migration and invasion were detected by wound healing and transwell assays, respectively. (the scale bar represented 200 μm in h, and represented 100 μm in i) (*p < 0.05, **p < 0.01, ***p < 0.001, compared with pcDNA3 or siRNA NC+pcDNA3, #p < 0.05, ##p < 0.01, compared with siUBAP2L+pcDNA3)

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

c-Myc Antibody - #AF6054